Mike Sherman

Mike Sherman has over 30 years of experience in the life sciences industry, with a track record of leadership as CEO and Board Director across multiple public and private companies. He currently serves as an independent Board Director at Werewolf Therapeutics and Tolremo Therapeutics, both focused on advancing novel cancer therapeutics.

Most recently, Mr. Sherman served as CEO and then Chair of the Board at Chimerix, where he led the company’s strategic transformation from a focus on antivirals to oncology drug development. Under his leadership, Chimerix achieved FDA approval and the subsequent sale of its antiviral drug, TEMBEXA®. The company’s lead oncology asset, ONC201, is currently under FDA review for the treatment of a genetically defined form of brain cancer primarily affecting children and young adults. This clinical, regulatory, and strategic progress led to the $935 million acquisition of Chimerix by Jazz Pharmaceuticals in 2025.

Prior to Chimerix, Mr. Sherman served as CEO of Endocyte, where he led one of the industry’s more notable turnarounds—guiding the company from a $200 million market capitalization to its $2.1 billion acquisition by Novartis in 2018. He repositioned Endocyte by re-prioritizing the pipeline, acquiring an external radiopharmaceutical asset, and rapidly executing a Phase 3 development strategy. That asset, now known as PLUVICTO®, is an FDA-approved treatment for advanced prostate cancer and is used by tens of thousands of patients annually. Mr. Sherman initially joined Endocyte in 2006 as Chief Financial Officer and played a pivotal role in the company’s IPO and several subsequent private and public financings.

Earlier in his career, Mr. Sherman held senior executive roles at Guidant Corporation, where he supported both U.S. and European operations prior to the company’s acquisition by Boston Scientific.

Mr. Sherman holds a BA in Economics from DePauw University, where he was a Management Fellow, and an MBA from the Tuck School of Business at Dartmouth, where he graduated as a Tuck Scholar. His prior board service also includes Biospecifics Technologies (acquired by Endo Pharmaceuticals), Mead Johnson Nutrition (acquired by Reckitt Benckiser), and the Children’s Museum of Indianapolis, where he served as Chair of the Board of Trustees.